NCT04470674 Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients Status WITHDRAWN Phase PHASE2
NCT04466917 A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer Status WITHDRAWN Phase PHASE3
NCT04464174 Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer Status COMPLETED Phase PHASE2
NCT04459611 Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC(neoSCORE) Status UNKNOWN Phase PHASE2
NCT04458909 Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Status TERMINATED Phase PHASE3
NCT04455594 Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC Status NOT_YET_RECRUITING Phase PHASE2
NCT04452214 A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Status COMPLETED Phase PHASE1
NCT04444921 EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04443348 Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04440358 Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM Status COMPLETED Phase PHASE1/PHASE2
NCT04425135 Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC Status UNKNOWN Phase PHASE2
NCT04422392 Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT04422210 A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Status TERMINATED Phase PHASE1
NCT04419181 Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer Status WITHDRAWN Phase PHASE2
NCT04417088 Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy Status COMPLETED Phase PHASE1/PHASE2
NCT04416035 A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC Status UNKNOWN Phase PHASE3
NCT04410796 Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Status RECRUITING Phase PHASE2
NCT04405674 Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Status UNKNOWN Phase PHASE2
NCT04391049 Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Status ACTIVE_NOT_RECRUITING Phase PHASE1